Bibliography
- Papers of special note have been highlighted as either of interest (•) or of considerable interest (••) to readers.
- Rutkowski P, Debiec-Rychter M, Ruka W. Gastrointestinal stromal tumors: key to diagnosis and choice of therapy. Mol Diagn Ther. 2008;12:131–143.
- ESMO/European Sarcoma Network Working Group. Gastrointestinal stromal tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25(Suppl. 3):iii21–iii26.
- Heinrich MC, Owzar K, Corless CL, et al. Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase 3 Trial of imatynib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group. J Clin Oncol. 2008;26:5360–5367.
- Reichardt P, Blay JY, von Mehren M. Towards global consensus in the treatment of gastrointestinal stromal tumor. Expert Rev Anticancer Ther. 2010;10:221–232.
- Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002;347:472–480.
- Rutkowski P, Andrzejuk J, Bylina E, et al. What are the current outcomes of advanced gastrointestinal stromal tumors: who are the long-term survivors treated initially with imatinib. Med Oncol. 2013;30(4):765.
- Antonescu CR, Besmar P, Guo T, et al. Acquired resistance to imatinib in gastrointestinal stromal tumor occur through secondary gene mutation. Clin Cancer Res. 2005;11:4182–4190.
- Demetri GD, van Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumor after failure of imatinib: a randomized controlled trial. Lancet. 2006;368:1329–1338.
- Ferraro D, Zalcberg J. Regorafenib in gastrointestinal stromal tumors: clinical evidence and place in therapy. Ther Adv Med Oncol. 2014;6(5):222–228.
- Wilhelm S, Adnane J, Hirth-Dietrich C, et al. Preclinical characterization of BAY 73-4506: a kinase inhibitor with broad spectrum antitumor activity targeting oncogenic and angiogenic kinases. AACR-NCI-EORTC 2007 Conference: Abstr. B260.
- Wilhelm SM, Dumas J, Adnane L, et al. Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer. 2011;129:245–255.
- Rey JB, Launay-Vacher V, Tournigand C. Regorafenib as a single-agent in the treatment of patients with gastrointestinal tumors: an overview for pharmacists. Target Oncol. 2015;10:199–213.
- Overton LC, Heinrich MC. Regorafenib for treatment of advanced gastrointestinal stromal tumors. Expert Opin Pharmacother. 2014;15(4):549–558.
- Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004;64(19):7099–7109.
- European Medicines Agency. Stivarga: summary of product characteristics. 2015 [cited 2015 Sep 4]. Available from: http://www.ema.europa.eu
- Mross K, Frost A, Steinbild S, et al. A phase I dose-escalation study of regorafenib (BAY 73–4506), an inhibitor of oncogenic, angiogenic, and stromal kinases, in patients with advanced solid tumors. Clin Cancer Res. 2012;18:2658–2667.
- Strumberg D, Scheulen ME, Schultheis B, et al. Regorafenib (BAY73–4506) inadvancedcolorectalcancer:a phase I study. Br J Cancer. 2012;106:1722–1727.
- George S, Wang Q, Heinrich MC, et al. Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial. J Clin Oncol. 2012;30(19):2401–2407.
• Phase II trial demonstrating activity of regorafenib in advanced, imatinib/sunitnib resistant GIST.
- Van den Abbeele AD, Tanaka Y, Locascio T, et al. Assessment of regorafenib activity with FDG-PET/CT in a multicenter phase II study in patients (pts) with advanced gastrointestinal stromal tumor (GIST) following failure of standard therapy (Rx) [abstract]. J Clin Oncol. 2011;29:10050.
- George S, Feng Y, von Mehren M, et al. Prolonged survival and disease control in the academic phase II trial of regorafenib in GIST: response based on genotype. ASCO Meet Abstr. 2013;31:1051.
- Demetri GD, Reichardt P, Kang YK, et al. GRID study investigators. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;381(9863):295–302.
••Pivotal phase III study of regorafenib in metastatic/unresectable, progressive GIST. The results of this study led to worldwide-approval of regorafenib for treatment of advanced GIST after failure of prior treatment with imatinib and sunitinib.
- Shinagare AB, Jagannathan JP, Kurra V, et al. Comparison of performance of various tumour response criteria in assessment of regorafenib activity in advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib. Eur J Cancer. 2014;50(5):981–986.
- Demetri GD, Jeffers M, Reichardt P, et al. Mutational analysis of plasma DNA from patients (pts) in the phase III GRID study of regorafenib (REG) versus placebo (PL) in tyrosine kinase inhibitor (TKI)-refractory GIST: correlating genotype with clinical outcomes. J Clin Oncol. 2013;31:suppl; abstr 10503.
- Grothey A, George S, van Cutsem E, et al. Optimizing treatment outcomes with regorafenib: personalized dosing and other strategies to support patient care. Oncologist. 2014;19(6):669–680.
• Comprehensive review on regorafenib toxicity and its management.
- De Wit M, Boers-Doets CB, Saettini A, et al. Prevention and management of adverse events related to regorafenib. Support Care Cancer. 2014;22(3):837–846.
- Poole CD, Connolly MP, Chang J, et al. Health utility of patients with advanced gastrointestinal stromal tumors (GIST) after failure of imatinib and sunitinib: findings from GRID, a randomized, double-blind, placebo-controlled phase III study of regorafenib versus placebo. Gastric Cancer. 2015;18:627–634.
- Serrano C, George S. Recent advances in the treatment of gastrointestinal stromal tumors. Ther Adv Med Oncol. 2014;6(3):115–127.
- Wu L, Zhang Z, Yao H, et al. Clinical efficacy of second-generation tyrosine kinase inhibitors in imatinib-resistant gastrointestinal stromal tumors: a meta-analysis of recent clinical trials. Drug Des Devel Ther. 2014;30(8):2061–2067.
- Jones RL, Bendell JC, Smith DC, et al. A phase I open-label trial evaluating the cardiovascular safety of regorafenib in patients with advanced cancer. Cancer Chemother Pharmacol. 2015;76(4):777–784.
- Shirley M, Keating GM. Regorafenib: a review of its use in patients with advanced gastrointestinal stromal tumours. Drugs. 2015;75(9):1009–1017.
- Rutkowski P, Ruka W. Emergency surgery in the era of molecular treatment of solid tumours. Lancet Oncol. 2009;10(2):157–163.
- Heinrich MC, Fletcher JC, Anjum R, et al. Use of ponatinib to inhibit kinase mutations associated with drug-resistant gastrointestinal stromal tumors (GIST). J Clin Oncol. 2013;31(Suppl): abstract 10509.